# MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy

> **NCT01294306** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 80 (actual)

## Conditions studied

- Adenosquamous Lung Carcinoma
- Bronchioloalveolar Carcinoma
- Large Cell Lung Carcinoma
- Lung Adenocarcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- Squamous Cell Lung Carcinoma

## Interventions

- **DRUG:** Akt Inhibitor MK2206
- **DRUG:** Erlotinib Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01294306
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-02
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2016-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294306

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294306, "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01294306. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*